Make an Inquiry

    Sorry, We are 100% Exporting company, We are not selling in India.

    Levofloxacin Infusion


    Product/Composition:-

    Levofloxacin Infusion

    Strength:-

    100 ml

    Form:-

    Infusion

    Production Capacity

    1 Million Infusion/Month

    Levofloxacin solution for infusion is indicated in adults for the treatment of the following infections (see sections 4.4 and .1),Communityacquired pneumonia Complicated skin and soft tissue infections, For the above-mentioned infections levofloxacin should be used only when it is nsidered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.

    Levofloxacin solution for infusion is indicated in adults for the treatment of the following infections (see sections 4.4 and .1),Communityacquired pneumonia Complicated skin and soft tissue infections, For the above-mentioned infections levofloxacin should be used only when it is nsidered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.

    Levofloxacin solution is administered by slow intravenous infusion once or twice daily. The dosage depends in the type and severity of the infection and the susceptibility of the presumed causative pathogen. Treatment with levofloxacin after the initial use of the intravenous preparation may be completed with an appropriate oral levofloxacin presentation, in accordance with it's SPC, and as considered appropriate for the individual patient. Given the bioequivalence of the parenteral and oral forms, the same dosage can be used. Levofloxacin solution for infusion is only intended for slow intravenous infusion; it is administered once or twice daily.

    The infusion time must be at least 30 minutes for 250 mg or 60 minutes for 500 mg levofloxacin.Methicillin-resistant Staphylococcus aureus (MRSA) are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA infections are considered inappropriate).

    Read more...

    Tages :